Type 2 Diabetes Connect
  • Saved

1mo

Beyond HbA1c, what most commonly drives therapy intensification in Type 2 diabetes?

  • Saved

2mo
GLP-1 Agonists in Adolescent Obesity: A Narrative Review of Single, Dual, and Triple Agonists. - PubMed

GLP-1 Agonists in Adolescent Obesity: A Narrative Review of Single, Dual, and Triple Agonists. - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/42318576

Explore GLP-1 receptor agonists in adolescent obesity management. Dual and triple agonists require further pediatric trials to confirm efficacy.


GLP-1 agonists show significant weight reduction in adolescent obesity; STEP TEENS trial noted 16% reduction. Dual/triple agonists need more pediatric data.

  • Saved

2mo
DDW 2026 highlights colorectal cancer screening, GLP-1 research, and Crohn’s disease therapy

Asma Shaukat, MD, Professor of Medicine at NYU Grossman School of Medicine and outgoing Chair of the Clinical Practice Section for the AGA Council, discussed 13-year Nordic trial findings showing reduced colorectal cancer incidence with colonoscopy screening, along with emerging data on GLP-1 therapies in fatty liver disease and cirrhosis. Bruce Sands, MD, Chief of Gastroenterology and Professor of Medicine at the Icahn School of Medicine at Mount Sinai, presented findings from the DUET-CD study evaluating combination therapy in Crohn’s disease.

  • Saved

2mo
Comparative effects of different intensities of aerobic and resistance exercise on glycemic control and cardiorespiratory fitness in middle-aged older patients with type 2 diabetes: a network meta-analysis. - PubMed

Comparative effects of different intensities of aerobic and resistance exercise on glycemic control and cardiorespiratory fitness in middle-aged older patients with type 2 diabetes: a network meta-analysis. - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/42267276

Discover how exercise intensities affect glycemic control in older adults with type 2 diabetes. High-intensity resistance training shows promising results.


High-intensity resistance training significantly reduces HbA1c in type 2 diabetes compared to usual care, with moderate-certainty evidence.

  • Saved

2mo
Efficacy and safety of GLP-1 receptor agonists in MASH with fibrosis: A systematic review and meta-analysis - PubMed

Efficacy and safety of GLP-1 receptor agonists in MASH with fibrosis: A systematic review and meta-analysis - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/41810433/

Metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis is a major driver of liver-related morbidity and mortality, yet effective pharmacologic options remain limited. This meta-analysis shows that glucagon-like peptide-1 receptor agonists (GLP-1...

Meta-analysis of 7 RCTs found GLP-1 receptor agonists significantly improve MASH resolution and fibrosis in patients with F2–F3 fibrosis, while also improving cardiometabolic risk factors, with mainly gastrointestinal adverse effects and no increase in serious adverse events.